Related Experiment Video
Updated: Mar 28, 2026
Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings
Published on: February 7, 2025
Safety of a thickened extensive casein hydrolysate formula
Yvan Vandenplas1, Elisabeth De Greef1, I Xinias2
1UZ Brussel, Department of Pediatrics, Vrije Universiteit Brussel, Brussels, Belgium.
Insights
Extensively casein hydrolyzed protein formulas (eCHF) effectively manage cow's milk allergy (CMA) in infants. Both thickened (T-eCHF) and non-thickened (NT-eCHF) formulas demonstrated nutritional safety and symptom reduction in infants with CMA.
Area of Science:
- Pediatric Nutrition
- Allergy and Immunology
Background:
- Cow's milk allergy (CMA) is a common condition in infants.
- Extensive protein hydrolysate formulas are typically used for managing CMA.
- Nutritional safety and efficacy of thickened versus non-thickened formulas require evaluation.
Purpose of the Study:
- To assess the nutritional safety of a non-thickened (NT-eCHF) and thickened (T-eCHF) extensively casein hydrolyzed protein formula.
- To evaluate the efficacy of these formulas in reducing CMA symptoms in infants.
Main Methods:
- Infants under 6 months with confirmed CMA were enrolled.
- Growth parameters (weight and length) were monitored over a 6-month intervention period.
- Stool consistency was assessed to evaluate formula efficacy.
Main Results:
- All infants with confirmed CMA tolerated the extensively casein hydrolyzed protein formula (eCHF).
- The thickened extensively casein hydrolyzed protein formula (T-eCHF) significantly improved stool consistency.
- Infant growth (height and weight) remained satisfactory throughout the study.
Conclusions:
- Extensively casein hydrolyzed protein formulas (eCHF) meet hypoallergenic criteria for infants with CMA.
- Both NT-eCHF and T-eCHF effectively reduced CMA symptoms.
- The formulas supported normal growth in infants with cow's milk allergy.
Objectives:
Cow's milk allergy (CMA) is treated in formula-fed infants with an extensive protein hydrolysate. This study aimed to evaluate the nutritional safety of a non-thickened and thickened extensively casein hydrolyzed protein formula (NT- and T-eCHF) in infants with CMA.
Methods:
Infants younger than 6 mo old with a positive cow milk challenge test, positive IgE, or skin prick test for cow milk were selected. Weight and length were followed during the 6 mo intervention with the NT-eCHF and T-eCHF.
Results:
A challenge was performed in 50/71 infants with suspected CMA and was positive in 34/50. All children with confirmed CMA tolerated the eCHF. The T-eCHF leads to a significant improvement of the stool consistency in the whole population and in the subpopulation of infants with proven CMA. Height and weight evolution was satisfactory throughout the 6 mo study.
Conclusions:
The eCHF fulfills the criteria of a hypoallergenic formula and the NT- and T-eCHF reduced CMA symptoms. Growth was within normal range.
More Related Videos
09:36Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
